trending Market Intelligence /marketintelligence/en/news-insights/trending/VQhuA89gHhfKQ9B0ecJ0vg2 content esgSubNav
In This List

Amgen to incur over $6B in tax expense following tax overhaul

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Amgen to incur over $6B in tax expense following tax overhaul

Amgen Inc. expects to incur net tax expense of between $6 billion and $6.5 billion due to the U.S. tax bill that was just signed into law.

The net tax expense is related to the repatriation tax and the revaluation of net deferred tax liabilities. This charge will impact the company's previously provided GAAP EPS and tax rate guidance for 2017 but will not affect its non-GAAP guidance.

Going forward, Amgen does not expect an increase in its non-GAAP tax rates as a result of the legislation.

Due to the legislation, Amgen's future U.S. income generally will be taxed at the 21% U.S. corporate income tax rate, while its income elsewhere, including Puerto Rico, will generally be taxed in the U.S. at 10.5%, reduced by foreign tax credits.

The drugmaker will provide an update to its GAAP tax expense associated with the tax law in its fourth-quarter 2017 earnings call on or about Feb. 1, 2018.